首页> 外文期刊>Therapeutic Drug Monitoring >Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders
【24h】

Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders

机译:重度抑郁症患者血浆帕罗西汀的治疗参考范围

获取原文
获取原文并翻译 | 示例
           

摘要

Background: We investigated the relationship between plasma concentrations of paroxetine and the therapeutic effect of the drug, and we evaluated the therapeutic reference range for plasma concentration of paroxetine in patients with major depressive disorders (MDD). Methods: In this study, 120 patients with MDD were treated with 10-40 mg/d of paroxetine for 6 weeks, and 89 patients completed the protocol. The Montgomery-Asberg Depression Rating Scale (MADRS) was used to evaluate the patients at 0, 1, 2, 4, and 6 weeks. At the 6-week treatment time point, the patients were divided into 7 groups according to their paroxetine plasma concentrations in increments of 20 ng/mL. We used an analysis of variance and a χ2 test to define the therapeutic reference range for plasma paroxetine concentrations. Results: We used 50% as the cutoff values for the percentage of MADRS improvement to determine the responder rates, and we defined remitters as patients with MADRS scores 10 at the 6-week treatment time point. We analyzed the responder and remitter rates of the patients according to their plasma paroxetine concentrations: 20 ng/mL, 40 ng/mL, and 60 ng/mL using the χ2 test. According to the results of the χ test in the responder rates, the 20-60 ng/mL plasma paroxetine group showed the highest effect size. Conclusions: The results of this study suggested that a range of 20-60 ng/mL is the therapeutic reference range for concentrations of paroxetine in plasma in patients with MDD.
机译:背景:我们研究了帕罗西汀血浆浓度与药物治疗效果之间的关系,并评估了重度抑郁症(MDD)患者帕罗西汀血浆浓度的治疗参考范围。方法:在这项研究中,对120例MDD患者接受10-40 mg / d的帕罗西汀治疗6周,其中89例患者完成了方案。使用蒙哥马利-阿斯伯格抑郁量表(MADRS)评估患者在0、1、2、4和6周时的情况。在6周的治疗时间点,根据帕罗西汀的血浆浓度以20 ng / mL的增量将患者分为7组。我们使用方差分析和χ2检验确定血浆帕罗西汀浓度的治疗参考范围。结果:我们使用50%作为MADRS改善百分比的临界值来确定缓解率,并且将缓解者定义为在6周治疗时间点MADRS得分<10的患者。我们使用χ2检验根据患者血浆帕罗西汀浓度:20 ng / mL,40 ng / mL和60 ng / mL分析了患者的缓解率和缓解率。根据χ检验的应答率结果,血浆帕罗西汀组20-60 ng / mL表现出最大的效应量。结论:这项研究的结果表明,MDD患者血浆中帕罗西汀的浓度治疗参考范围为20-60 ng / mL。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号